Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial

NCT07767552 · Not yet recruiting

Last updated 2026-08-27

This study tested whether the experimental drug mazudutide could help adults with type 2 diabetes achieve normal blood sugar levels without diabetes medications after 44 weeks of treatment.

Status Not yet recruiting Approved but enrollment has not started.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 249 people Planned (estimated).

Who can join Ages 18–70 · all sexes

Timeline Started 2026-09 · est. completion 2029-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07767552 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate and efficacy of Mastitide for diabetes remission in Chinese type 2 diabetic subjects with poor glycemic control on diet or exercise therapy alone or metformin/sodium-glucose cotransporter (SGLT2) inhibitor monotherapy.

Treatments tested

Mazdutide Drug

GLP-1 receptor/glucagon receptor (GLP-1R/GCGR) dual agonist, administered by subcutaneous injection once weekly using a pre-filled pen device. Titration from 2 mg QW (weeks 0-4) to 4 mg QW (weeks 5-8) to 6 mg QW (weeks 9-24). Injection sites: abdomen, anterior-lateral thigh, or lateral upper arm, rotated at each injection.
Placebo Drug

Matching placebo for mazdutide, administered by subcutaneous injection once weekly using a pre-filled pen device identical in appearance, color, volume, and packaging to the active drug pen. Titration schedule mirrors the 6 mg mazdutide arm to maintain blinding.

Main thing measured	Proportion of Participants Achieving Normal Glucose Regulation (NGR) at Week 44
Sponsor	Yanbing Li
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	mazdutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07767552 ↗